To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The value of adding a single co-test in HPV primary screening
Department of Women’s Health, Faculty of Medicine and Health, Örebro University, Örebro, Sweden .
Örebro University, School of Medical Sciences. Department of Women’s Health.ORCID iD: 0009-0002-1983-5422
Örebro University, School of Health Sciences. Örebro University, School of Medical Sciences. Department of Women’s Health.ORCID iD: 0000-0002-1458-1542
Örebro University, School of Medical Sciences. Department of Laboratory Medicine.ORCID iD: 0000-0003-2317-5738
2021 (English)In: Preventive Medicine, ISSN 0091-7435, E-ISSN 1096-0260, Vol. 149, article id 106617Article in journal (Refereed) Published
Abstract [en]

The screening program for cervical cancer in Sweden, recommends screening with HPV test primarily for women over 30 years, but at the first screening test that is performed after the age of 40, both HPV test and cytology is recommended, so-called co-testing. The aim of this study was to examine how many cases of HPV negative cervical dysplasia that were found in this age-group, to be able to estimate the value of adding a co-test in an HPV screening program. A retrospective study of all abnormal cytological samples found in the cytology based screening program in the age group 41-45 years during the years 2012-2016 in the Region of center dot Orebro County was performed. Out of the 10,511 women included in the study, 468 had an abnormal cytology screening test and 255/468 were HPV negative. The vast majority of the HPV negative cases had a normal cytology test as first follow-up. Of cases with remaining cytological abnormality, only four cases had histologically confirmed highgrade cervical dysplasia (CIN2) and no cases of HPV negative adenocarcinoma in situ or invasive cancer were found. Conclusion: With adding a single co-test to a HPV-based screening program, only a few extra cases of highgrade cervical dysplasia were found and the clinical significance of these cases is unclear.

Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 149, article id 106617
Keywords [en]
Cervical intraepithelial neoplasia, Human papillomavirus, Uterine cervical neoplasms, Early detection of cancer, Screening
National Category
Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
URN: urn:nbn:se:oru:diva-93193DOI: 10.1016/j.ypmed.2021.106617ISI: 000659230000010PubMedID: 33984370Scopus ID: 2-s2.0-85105814926OAI: oai:DiVA.org:oru-93193DiVA, id: diva2:1582248
Note

Funding Agency:

Research Committee of Örebro County Council 

Available from: 2021-07-29 Created: 2021-07-29 Last updated: 2025-02-11Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Zetterström, KarinBergengren, LovisaHelenius, Gisela

Search in DiVA

By author/editor
Zetterström, KarinBergengren, LovisaHelenius, Gisela
By organisation
School of Medical SciencesSchool of Health Sciences
In the same journal
Preventive Medicine
Gynaecology, Obstetrics and Reproductive Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 82 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf